GlassScriptPhysician profile
Bal K Srivastava
NPI 1871592345
$9,652.55
in general payments reported to CMS, 2019-2025
31 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $1,294 · 2021: $1,862 · 2022: $1,419 · 2023: $1,705 · 2024: $1,248 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,818 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,817.87 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,275.61 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,277.49 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Janssen Pharmaceuticals, INC | $809.68 | 2019-2024 | Xarelto |
| Pfizer INC. | $786.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $682.12 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $591.32 | 2021-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.38 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $526.57 | 2020-2022 | |
| Boston Scientific Corporation | $517.19 | 2019-2025 | Watchman Access System, Watchman Flx |
| Astellas Pharma US INC | $309.52 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $194.52 | 2022-2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.53 | 2019-2025 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $138.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.58 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $119.46 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $109.38 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $81.04 | 2019 | |
| Esperion Therapeutics, INC. | $79.08 | 2021-2025 | Nexletol |
| Abiomed | $54.74 | 2024-2025 | Impella |
| Novo Nordisk INC | $54.07 | 2024-2025 | Wegovy |
| Arbor Pharmaceuticals, INC. | $26.64 | 2021 | |
| Kestra Medical Technology Services, INC. | $25.50 | 2025 | Assure Wcd |
| Medicomp INC | $20.00 | 2023 | Telepatch Cardiac Monitor |
| Lilly USA, LLC | $18.85 | 2025 | Zepbound |
| Cashflow Solutions, LLC | $18.58 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Scpharmaceuticals INC. | $16.31 | 2024 | |
| Cvrx, INC. | $16.06 | 2023 | Barostim Neo System |
| Daiichi Sankyo INC. | $14.30 | 2021 | |
| Biosense Webster, INC. | $13.95 | 2020 | |
| Amryt Pharma Holdings LTD | $12.59 | 2021 | |
| Cmp Pharma, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bal Srivastava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.